AbCellera Collaborates With Vertex Pharma on Drug Discovery for Autoimmune Diseases
AbCellera (ABCL) has entered into a collaboration with Vertex Pharmaceuticals (VRTX) focused on the discovery and early research of T-cell engagers targeting autoimmune diseases. The partnership will utilize AbCellera's advanced technologies to identify potential therapies in this area. The deal highlights growing interest among biotech firms in developing innovative treatments for complex immune-related conditions, leveraging cutting-edge platforms like those offered by AbCellera.
Tickers: $VRTX
Topics: autoimmune diseases biotech collaboration T-cell engagers